Cancer Research Annual Meeting 2010 Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stevens, A.
Right arrow Articles by Ray, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stevens, A.
Right arrow Articles by Ray, D. W.
[Cancer Research 63, 812-816, February 15, 2003]
© 2003 American Association for Cancer Research

Endocrinology

Haplotype Analysis of the Polymorphic Human Vascular Endothelial Growth Factor Gene Promoter1

Adam Stevens, Joanne Soden, Paul E. Brenchley, Shirley Ralph and David W. Ray2

Endocrine Sciences Research Group [A. S., J. S., D. W. R.] and Department of Medicine [P. E. B., S. R.], Stopford Building, University of Manchester, Manchester M13 9PT, United Kingdom


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The human vascular endothelial growth factor (VEGF) gene is unusually polymorphic,and there is evidence for inheritance of conserved haplotypes.One haplotype, carrying polymorphisms at -460/+405, is associated with enhanced production of VEGF in vitro. The VEGF promoter is activated by phorbol esters and, in endometrial cells, by estrogen. We have analyzed the impact of the common -460/+405 polymorphism on both basal and stimulated VEGF transcription using the human breast cancer cell line MCF7. Because the VEGF promoter is so highly polymorphic, haplotypes were established and analyzed. Carriage of the -460/+405 polymorphisms increased basal promoter activity by 71% compared with the wild-type sequence. However, this effect was dependent on colinearity with a series of further 5' sequence polymorphisms. The -460/+405 polymorphism also increased the mean induction by phorbol ester from 5-fold to 8.5-fold. In contrast to earlier studies in endometrial cells, none of the human VEGF promoter constructs was regulated by estrogen. Overexpression of the estrogen receptor did not confer estrogen regulation to VEGF, implying cell type-specific hormonal regulation. Therefore, carriage of the -460/+405 polymorphism significantly alters VEGF promoter activity and responsiveness. This has implications for the inherited susceptibility of common diseases.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Angiogenesis only occurs in normal adult tissues during wound healing and in the female reproductive cycle but is activated in disease.VEGF3 is one of the most potent and specific angiogenic factors (1 , 2) , and increased VEGF expression and associated pathogenic angiogenesis are found in tumors (3) , rheumatoid arthritis (4) , and diabetic retinopathy (5) .

Numerous studies have shown that growing tumors require the establishment of a blood supply (6) , and VEGF is often up-regulated in cancer (1) . Indeed interruption of VEGF action profoundly inhibits tumorigenesis (7 , 8) . Recent work has identified cell type-specific enhancers within the VEGF promoter that up-regulate VEGF expression in glioblastoma (9) , a tumor type that abundantly expresses VEGF and is particularly dependent on VEGF for its aggressive growth (10) .

The VEGF gene is located on chromosome 6p21.3 (11) and consists of eight exons exhibiting alternate splicing to form a family of proteins (12) . The VEGF gene is reported to be regulated by estrogen, hypoxia, growth factors including epidermal growth factor, and cytokines including interleukin 6 (13, 14, 15, 16) . There is considerable variation between individuals in VEGF expression, and analysis of the 5'-flanking region of the gene has shown the presence of many polymorphisms (17, 18, 19) .

The rat VEGF gene contains two ER-binding sites. One of these was in the 3'-untranslated region and worked as a conventional enhancer, and the other, located in exon 1 (+410), appeared to repress transcription in the presence of estrogen (15) . Transfection analysis of the human VEGF promoter, in contrast, did reveal a positive estrogen response, which appeared to be conferred by a sequence at between -1526 and -1514 (16) .

One of the previously reported polymorphisms (+405 G to C) is located adjacent to the +410 ERE that was identified in the rat VEGF gene and is highly conserved in the human, and an 18-nucleotide insertion at -1512 is located close to a further, putative upstream ERE between -1514 and -1526 (17 , 19) . The sequence (-1526-aatcagactgactgg-cctcagagccc) was found to bind ER in gel shift analysis; the site of the 18-nucleotide insertion identified by Brogan at -1512 is marked - (17 ; Fig. 1aCitation ). Therefore, it seemed likely that carriage of these polymorphisms would alter the estrogen responsiveness of the promoter, and, because they are frequent, this would have important implications for regulation of VEGF expression.



View larger version (49K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. a, diagram of the human VEGF promoter region. The amplification primer sequences are boxed; polymorphisms are marked with numbers relative to the transcription start site. The putative EREs are marked in red, and the AP-1 binding sites are marked in green. The transcription start site is marked with an arrow, and the transcribed nucleotides are marked in capital letters. b, diagram of VEGF gene haplotypes A (A), B (B), and C (C; wild type). The relationship between the polymorphisms identified is shown. Haplotype C (the wild-type promoter) was found to contain no sequence variation compared with the published sequence.

 
Several lines of evidence suggest the need for haplotype analysis of the human VEGF promoter. The human VEGF gene is highly polymorphic; some polymorphisms are frequent in the normal population (allele frequencies +405 G to C at 0.709; -1512 insertion at 0.675), and haplotype frequencies in the normal population suggest significant shared inheritance patterns (17 , 19) . Recent data suggest that linkage disequilibrium is highly structured into conserved blocks of sequence that are separated by recombination hot spots (20 , 21) . Within a conserved block, however, association studies will generally be insufficient to identify the causal polymorphism, and indeed, the overall function of a conserved haplotype may require interaction among polymorphisms for its final expression. It is proposed that within a conserved block, the precise location of a causal variant would be better identified based on biological function, rather than formal, statistical models (22) . Case-control studies have shown associations between polymorphisms of the VEGF gene and diabetic retinopathy (23) , preeclampsia (24) , and acute renal allograft rejection (25) .

This study sought to test the hypothesis that genetic polymorphisms in the 5' region of the VEGF promoter influence gene transcription. We analyzed haplotypes containing the common polymorphisms at -460 and +405 that have been associated with human disease in response to estrogen and phorbol esters.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Genotyped individuals homozygous for the two common VEGF -460 and +405 haplotypes (-460C/+405G and -460T/+405C) that account for 80.9% of the population were identified as described previously (19) . The VEGF promoter was amplified from genomic DNA using Qiagen proofstart DNA polymerase and the primers 5'-caggactagtgcacgaatga and 3'-tctgtctgtctgtccgtccg. Conditions were 35 cycles of 94°C for 50 s, 61°C for 50 s, and 72°C for 5min. The 2.3-kb band was excised from a 1% agarose gel (1x Tris acetate EDTA buffer) and cloned into a pGEM-T vector (Invitrogen). Clones were fully sequenced to exclude PCR errors, to confirm the presence of the predicted polymorphisms, and to allow the haplotype to be established. The promoter was excised using HindIII and XhoI before ligation into pGL3-luc (Promega). Clones were resequenced to confirm the haplotypes.

MCF7 cells were obtained from European Collection of Animal Cell Cultures and cultured in DMEM with 10% FCS (Life Technologies, Inc.). Cells were transfected using GeneJuice (Novagen), according to the manufacturer’s recommendations. All transfections were performed in sextuplicate, and cells were cotransfected with VEGF-luc or empty-luc and a cytomegalovirus-Renilla vector to control for transfection efficiency.

After transfection, cells were washed with serum-free, phenol red-free DMEM (Life Technologies, Inc.) and incubated with the same medium for 24 h. Cells were then treated with vehicle, PMA (Sigma, Poole, United Kingdom), 17ß-estradiol (Sigma), dexamethasone (Sigma), TNF-{alpha} (R&D Systems), or cptcAMP (Sigma) for 16 h before harvest. There was no effect seen with any of the vehicle concentrations used in this study.

Cells were analyzed using the Dual Luciferase kit (Promega), according to the manufacturer’s recommendations. All luciferase results were corrected for Renilla, which varied by less than 10% within each experiment.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Establishment of Haplotypes.
We amplified DNA from an individual who was homozygous for the -460C/+405G polymorphisms. From this individual, two alleles were amplified both with the predicted polymorphisms and the 18-nucleotide insertion and the -1540, -1451, and -152 polymorphisms (Fig. 1)Citation . The expected population frequencies of the +405G allele (0.709) and the -1540C to A/18-nucleotide insertion allele (0.675) are high, and therefore colinearity in a haplotype is not unexpected. However, the sequences differed at two other polymorphisms, -160C to T (allele frequency, 0.017) and -116G to A (allele frequency, 0.3). Both alleles also contained the unusual polymorphism -152G to A (allele frequency 0.017) and a novel variant, -1451C to T. The allele frequency of -1451C was 0.43 (determined from analysis of 36 individuals; GenBank accession number AY102626). Sequencing of multiple clones identified two alleles and excluded PCR errors. These two polymorphic haplotypes were termed A and B (Fig. 1)Citation .

Genomic DNA from one individual, genotyped as homozygous -460T/+405C (wild-type sequence), was amplified and found to correspond to the published sequence throughout. This was termed haplotype C.

Basal Promoter Activity of Polymorphic (VEGF Promoter.
Initial experiments compared the promoter activity of the empty plasmid pGL3-luc against the three different VEGF haplotypes. The VEGF DNA increased luciferase activity by greater than 100-fold, indicating the presence of significant promoter activity. Haplotype A showed consistently higher promoter activity compared with haplotypes B and C (Fig. 2)Citation .



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Expression of human VEGF haplotypes in human MCF7 cells. MCF7 cells were transfected with pGL3-luc constructs containing the VEGF gene haplotypes A (A), B (B), or wild-type (C) for comparison against empty pGL3-luc (pGL3). Cells were cotransfected with cytomegalovirus-Renilla to control for transfection efficiency. This experiment was performed in sextuplicate and is representative of experiments performed on three occasions. Results are expressed as corrected relative light units (RLU; mean ± SD).

 
Phorbol Ester Regulation of the Polymorphic VEGF Promoters.
The human VEGF gene promoter (haplotype C) used in these experiments contains multiple predicted AP-1 sites (Fig. 1)Citation and has previously been shown to be responsive to phorbol esters (16) . We found that the empty reporter gene pGL3-luc was not responsive to PMA but that haplotypes B and C both showed a 5-fold induction (Fig. 3)Citation . Haplotype A, which had a higher basal activity, showed an 8.5-fold induction in activity in response to PMA.



View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Regulation of human VEGF haplotypes by phorbol esters and cAMP. MCF7 cells were transfected with the VEGF haplotype reporter genes A, B, and C, and after transfection, cells were divided into treatment groups of 6. Cells were incubated with 10-7 M PMA, 250 µM cptcAMP, or nothing for 16 h before harvest. Results are expressed as fold induction over the control for each haplotype (mean ± SD).

 
Estrogen Regulation of Polymorphic VEGF Promoters.
The VEGF gene promoter does not contain a consensus ERE, but two candidate atypical EREs have been described. MCF7 is an estrogen-responsive, human breast cancer cell line. None of the VEGF promoters showed any induction of activity in response to 100 nM estradiol, nor did the pGL3-luc control. A previous report suggested that overexpression of ER might be required to manifest estrogen regulation of the VEGF promoter, and so we cotransfected an ER{alpha} expression vector with the VEGF constructs. Transfected cells were divided into treatment and control groups to eliminate differences in transfection efficiency. Again there was no estrogen response. The same ER{alpha} expression vector had been used to confer estrogen responsiveness to another human cancer cell line, confirming its authenticity (26) .

Regulation of VEGF Promoter by Other Agents.
In an effort to identify other signaling pathways that might differentially impact the polymorphic promoters, we examined the action of the synthetic glucocorticoid dexamethasone (100 nM; Sigma), the proinflammatory cytokine TNF-{alpha} (0.5 ng/ml; R and D Systems), and the cell-permeable, long-acting, cAMP analogue cptcAMP (250 µM; Sigma). None of these three agents altered the promoter activity of any of the three VEGF promoters (Fig. 4)Citation .



View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Regulation of VEGF haplotypes by glucocorticoid, estrogen, and TNF-{alpha}. MCF7 cells were transfected with the VEGF haplotype reporter genes, and after transfection, they were divided into treatment groups of 6. Cells were incubated with the indicated concentrations of dexamethasone (Dex), 17ß-estradiol (E2), or TNF-{alpha} (TNF) for 16 h before harvest. Results are expressed as fold induction over the control for each haplotype (mean ± SD).

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The human VEGF gene 5'-flanking region is very highly polymorphic, with some of the polymorphisms occurring at high frequency, and it is unclear which VEGF sequence is the most appropriate for analysis. This is important because significant associations are noted between genotype and both VEGF secretion and disease (19 , 23 , 25) . In this work, we define three haplotypes and identify differences in both basal promoter activity and responsiveness to stimulation. Furthermore, we have determined that the 2.3-kb segment of the human VEGF gene examined is not estrogen responsive in the ER-positive human breast cancer cell line MCF7, in contrast to previously published work in endometrial cells (16) .

Delineation of the VEGF promoter haplotypes is difficult because the sequence is highly polymorphic. Previously, tight linkage disequilibrium has been reported for some groups of polymorphisms. Notably, the -460/+405 polymorphisms are found together at a higher frequency than predicted from their allele frequencies, and the haplotype -460C/+405C was found in only 1 of 230 chromosomes examined (19) . Further upstream from the promoter, a -1540 C to A conversion was always found with the adjacent 18-nucleotide insertion at -1512 (17) , and -460C was always found with -152A in a further study (23) . Therefore, the identity of a few, preserved haplotypes is proposed, with superimposition of more recent polymorphisms (20, 21, 22) . For this reason, we sought to analyze the functional consequences of haplotypes containing the common -460C/+405G polymorphisms, which are in linkage disequilibrium (19) , and which have been found to be associated both with disease and altered VEGF production (19 , 23) . The VEGF sequence obtained from a -460 C/+405G individual showed two haplotypes, both with the 18-nucleotide insertion, -1540C to A, -1451C to T, and -152 G to A (17 , 19) . However, one allele contained the -160C to T, and the other contained the -116G to A. The haplotype -460 C/-152A/-116G/+405G occurs at a frequency of 16% in a Japanese population, and -460 C/-152A/-116A/+405G occurs at a frequency of 13% (23) . All of the other polymorphisms have been reported previously, but it was surprising to find them in the same haplotype as the -460 C/+405G on both chromosomes. Both chromosomes from the -460 T/+405C individual had wild-type VEGF sequence [estimated haplotype frequency in a Japanese population, 40% (23) ].

Because two haplotypes had been identified in the individual with -460 C/+405G, both were compared against the wild-type VEGF promoter. Under basal conditions, haplotype B did not differ from wild-type VEGF (haplotype C), suggesting that either carriage of the numerous polymorphisms did not significantly alter promoter function or that the polymorphisms represented two classes, one activating, and the other repressing. Therefore, the net impact of the polymorphisms would be dependent on colinearity, frequency, and nature. Haplotype B contained a frequent polymorphism -116G to A (allele frequency, 0.3), and haplotype A contained a different, unusual change, -160C to T (allele frequency, 0.017). Previous work has shown a correlation of the +405 genotype with production of VEGF in vitro (19) and in vivo (23) ; however, the extended haplotype of the +405 homozygotes in these studies was not determined. It is interesting that haplotype A consistently showed markedly higher VEGF promoter activity compared with either haplotype B or the wild-type promoter. It is not possible from this analysis to be certain whether this change is due to loss of the -116 polymorphism or gain of the -160 polymorphism. However, it is clear that some haplotypes containing the +405G allele are high VEGF expressors.

The earlier report showing higher VEGF production from PBML cells isolated from +405G individuals is compatible with the current data. Carriage of the +405G genotype has been shown to be in linkage disequilibrium with carriage of other polymorphisms (19) and, in some combinations (i.e., haplotype A), certainly results in substantially higher promoter activity.

It was of interest that none of the three human VEGF promoter sequences tested were estrogen responsive in MCF7 cells. Even overexpression of ER, sufficient to confer an estrogen response in other cell types, did not make VEGF responsive. The endometrium and breast are well known to differ in their responses to partial agonist estrogens (SERMs), with full agonist activity in endometrium compared with antagonist activity in breast. The mechanistic explanation for this appears to be differential expression of cofactor molecules (27) . Because VEGF does not have a consensus ERE, it is likely that the imperfect sequence only supports estrogen regulation in certain cell types. It is important that a functional ERE in the rat VEGF gene is located 3' to the gene coding sequence, a region not present in the constructs used in the current study (15) .

In summary, we find that carriage of common VEGF polymorphisms alters both basal and post-stimulation promoter activity. There is clear evidence for a haplotype effect. A comprehensive analysis of recombination hot spots and possible haplotypes across this locus would be of interest and would aid association studies with human disease and ultimately gene linkage analysis (22) . The relative contributions of the colinear polymorphisms are also of interest. It seems likely that the highly polymorphic VEGF gene will contribute to the inherited predisposition to diseases in which angiogenesis plays a part.


   ACKNOWLEDGMENTS
 
We are grateful to the Central Manchester Healthcare Trust for their support. Dr. Ray is a GSK Fellow.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 D. W. R. was supported by a GlaxoWellcome Fellowship. Back

2 To whom requests for reprints should be addressed, at Endocrine Sciences Research Group, University of Manchester Medical School, Stopford Building, Oxford Road, Manchester M13 9PT, United Kingdom. Phone: 44-161-275-5655; Fax: 44-161-275-5180; E-mail: David.W.Ray{at}man.ac.uk Back

3 The abbreviations used are: VEGF, vascular endothelial growth factor; ER, estrogen receptor; TNF, tumor necrosis factor; ERE, estrogen response element; PMA, phorbol myristate acetate; PBML, peripheral blood mononuclear leukocytes; SERM, selective estrogen receptor modulator. Back

Received 7/ 5/02. Accepted 12/16/02.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res., 55: 15-35, 2000.
  2. Ferrara N., Gerber H. P. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol., 106: 148-156, 2001.[Medline]
  3. Oku T., Tjuvajev J. G., Miyagawa T., Sasajima T., Joshi A., Joshi R., Finn R., Claffey K. P., Blasberg R. G. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res., 58: 4185-4192, 1998.[Abstract/Free Full Text]
  4. Koch A. E., Harlow L. A., Haines G. K., Amento E. P., Unemori E. N., Wong W-L., Pope R. M., Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol., 152: 4149-4156, 1994.[Abstract]
  5. Miller J. W., Adamis A. P., Aiello L. P. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab. Rev., 13: 37-50, 1997.[Medline]
  6. Carmeliet P., Jain R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.[Medline]
  7. Shi Y. P., Ferrara N. Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF). Biochem. Biophys. Res. Commun., 254: 480-483, 1999.[Medline]
  8. Lee C. G., Heijn M., di Tomaso E., Griffon-Etienne G., Ancukiewicz M., Koike C., Park K. R., Ferrara N., Jain R. K., Suit H. D., Boucher Y. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res., 60: 5565-5570, 2000.[Abstract/Free Full Text]
  9. Liang Y., Xiao-Yong L., Rebar E. J., Li P., Zhou Y., Chen B., Wolffe A. P., Case C. C. Activation of vascular endothelial growth factor A transcription in tumorigenic glioblastoma cell lines by an enhancer with cell type-specific DNase I accessibility. J. Biol. Chem., 277: 20087-20094, 2002.[Abstract/Free Full Text]
  10. Chaudhry I. H., O’Donovan D. G., Brenchley P. E., Reid H., Roberts I. S. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology, 39: 409-415, 2001.[Medline]
  11. Vincenti V., Cassano C., Rocchi M., Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation, 93: 1493-1495, 1996.[Abstract/Free Full Text]
  12. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J. C., Abraham J. A. The human gene for vascular endothelial growth factor.Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem., 266: 11947-11954, 1991.[Abstract/Free Full Text]
  13. Klagsbrun M., D’Amore P. A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev., 7: 259-270, 1996.[Medline]
  14. Hyder S. M., Stancel G. M., Chiappetta C., Murthy L., Boettger-Tong H. L., Makela S. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res., 56: 3954-3960, 1996.[Abstract/Free Full Text]
  15. Hyder S. M., Nawaz Z., Chiappetta C., Stancel G. M. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res., 60: 3183-3190, 2000.[Abstract/Free Full Text]
  16. Mueller M. D., Vigne J. L., Minchenko A., Lebovic D. I., Leitman D. C., Taylor R. N. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors {alpha} and ß. Proc. Natl. Acad. Sci. USA, 97: 10972-10977, 2000.[Abstract/Free Full Text]
  17. Brogan I. J., Khan N., Isaac K., Hutchinson J. A., Pravica V., Hutchinson I. V. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum. Immunol., 60: 1245-1249, 1999.[Medline]
  18. Schultz A., Lavie L., Hochberg I., Beyar R., Stone T., Skorecki K. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery circulation. Circulation, 100: 547-552, 2002.[Abstract/Free Full Text]
  19. Watson C. J., Webb N. J., Bottomley M. J., Brenchley P. E. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine, 12: 1232-1235, 2000.[Medline]
  20. Daly M. J., Rioux J. D., Schaffner S. F., Hudson T. J., Lander E. S. High-resolution haplotype structure in the human genome. Nat. Genet., 29: 229-232, 2001.[Medline]
  21. Rioux J. D., Daly M. J., Silverberg M. S., Lindblad K., Steinhart H., Cohen Z., Delmonte T., Kocher K., Miller K., Guschwan S., Kulbokas E-J., O’Leary S., Winchester E., Dewar K., Green T., Stone V., Chow C., Cohen A., Langelier D., Lapointe G., Gaudet D., Faith J., Branco N., Bull S. B., McLeod R. S., Griffiths A. M., Bitton A., Greenberg G. R., Lander E. S., Siminovitch K. A., Hudson T. J. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat. Genet., 29: 223-228, 2001.[Medline]
  22. Goldstein D. B. Islands of linkage disequilibrium. Nat. Genet., 29: 109-111, 2001.[Medline]
  23. Awata T., Inoue K., Kurihara S., Ohkubo T., Watanabe M., Inukai K., Inoue I., Katayama S. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type II diabetes. Diabetes, 5: 1635-1639, 2002.
  24. Brenchley P. E., Ralph S. A., Summers A. VEGF polymorphisms and renal pathologies. Adv. Nephrol. Necker Hosp., 32: 17-23, 2002.
  25. Shahbazi M., Fryer A. A., Pravica V., Brogan I. J., Ramsay H. M., Hutchinson I. V., Harden P. N. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J. Am. Soc. Nephrol., 13: 260-264, 2002.[Abstract/Free Full Text]
  26. Huynh T. T., Ray D. W., Brogan I. J., Stevens A., Davis J. R., White A., White A. Failure of steroid regulation of the MMTV promoter in a small cell lung cancer cell line is caused by a DNA sequence flanking the glucocorticoid response element. J. Endocrinol., 172: 295-302, 2002.[Abstract]
  27. Shang Y., Brown M. Molecular determinants for the tissue specificity of SERMs. Science (Wash. DC), 295: 2465-2468, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Ann OncolHome page
D. H. Kim, W. Xu, S. Kamel-Reid, X. Liu, C. W. Jung, S. Kim, and J. H. Lipton
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
Ann. Onc., October 29, 2009; (2009) mdp452v1.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Hussein, E. Askar, M. Elsaeid, and F. Schaefer
Functional polymorphisms in transforming growth factor-beta-1 (TGF{beta}-1) and vascular endothelial growth factor (VEGF) genes modify risk of renal parenchymal scarring following childhood urinary tract infection
Nephrol. Dial. Transplant., October 26, 2009; (2009) gfp532v1.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
Q. Liu, Y. Li, J. Zhao, D.-L. Sun, Y.-N. Duan, N. Wang, R.-M. Zhou, and S. Kang
Association of polymorphisms -1154G/A and -2578C/A in the vascular endothelial growth factor gene with decreased risk of endometriosis in Chinese women
Hum. Reprod., October 1, 2009; 24(10): 2660 - 2666.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
R. Zarbock, D. Hendig, C. Szliska, K. Kleesiek, and C. Gotting
Vascular endothelial growth factor gene polymorphisms as prognostic markers for ocular manifestations in pseudoxanthoma elasticum
Hum. Mol. Genet., September 1, 2009; 18(17): 3344 - 3351.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. P. Schneider, M. Radovich, and K. D. Miller
The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer
Clin. Cancer Res., September 1, 2009; 15(17): 5297 - 5302.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. A. Bradbury, R. Zhai, C. Ma, W. Xu, J. Hopkins, M. J. Kulke, K. Asomaning, Z. Wang, L. Su, R. S. Heist, et al.
Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis
Clin. Cancer Res., July 15, 2009; 15(14): 4680 - 4685.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Zhai, G. Liu, K. Asomaning, L. Su, M. H. Kulke, R. S. Heist, N. S. Nishioka, T. J. Lynch, J. C. Wain, X. Lin, et al.
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk
Carcinogenesis, December 1, 2008; 29(12): 2330 - 2334.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. P. Schneider, M. Wang, M. Radovich, G. W. Sledge, S. Badve, A. Thor, D. A. Flockhart, B. Hancock, N. Davidson, J. Gralow, et al.
Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
J. Clin. Oncol., October 1, 2008; 26(28): 4672 - 4678.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. J. Churchill, J. G. Carter, C. Ramsden, S. J. Turner, A. Yeung, P. E. C. Brenchley, and D. W. Ray
VEGF Polymorphisms Are Associated with Severity of Diabetic Retinopathy
Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3611 - 3616.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Patel, S. Ailawadhi, F. Hernandez-Ilizaliturri, and G. E. Wilding
Vascular Endothelial Growth Factor Polymorphisms in Early-Stage Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2008; 26(19): 3289 - 3290.
[Full Text] [PDF]

Home page
 JCOHome page
R. S. Heist, R. Zhai, G. Liu, W. Zhou, X. Lin, L. Su, K. Asomaning, T. J. Lynch, J. C. Wain, and D. C. Christiani
VEGF Polymorphisms and Survival in Early-Stage Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 20, 2008; 26(6): 856 - 862.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Zhai, G. Liu, W. Zhou, L. Su, R. S. Heist, T. J. Lynch, J. C. Wain, K. Asomaning, X. Lin, and D. C. Christiani
Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non-Small Cell Lung Cancer
Clin. Cancer Res., January 15, 2008; 14(2): 612 - 617.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. G. Kim, Y. S. Chae, S. K. Sohn, Y. Y. Cho, J. H. Moon, J. Y. Park, S. W. Jeon, I. T. Lee, G. S. Choi, and S.-H. Jun
Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer
Clin. Cancer Res., January 1, 2008; 14(1): 62 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
A. Y. Debrah, S. Mand, M. R. Toliat, Y. Marfo-Debrekyei, L. Batsa, P. Nurnberg, B. Lawson, O. Adjei, A. Hoerauf, and K. Pfarr
Plasma Vascular Endothelial Growth Factor-A (VEGF-A) and VEGF-A Gene Polymorphism are Associated with Hydrocele Development in Lymphatic Filariasis
Am J Trop Med Hyg, October 1, 2007; 77(4): 601 - 608.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
G. Kitsios and E. Zintzaras
Genetic Variation associated with Ischemic Heart Failure: A HuGE Review and Meta-Analysis
Am. J. Epidemiol., September 15, 2007; 166(6): 619 - 633.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
R Zhai, M N Gong, W Zhou, T B Thompson, P Kraft, L Su, and D C Christiani
Genotypes and haplotypes of the VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDS
Thorax, August 1, 2007; 62(8): 718 - 722.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
D. Chalothorn, J. A. Clayton, H. Zhang, D. Pomp, and J. E. Faber
Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains
Physiol Genomics, July 18, 2007; 30(2): 179 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Kim, S. Sohn, Y. Chae, Y. Cho, H-I Bae, G Yan, J. Park, M-H Lee, H. Chung, and W Yu
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer
Ann. Onc., June 1, 2007; 18(6): 1030 - 1036.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Buraczynska, P. Ksiazek, I. Baranowicz-Gaszczyk, and L. Jozwiak
Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients
Nephrol. Dial. Transplant., March 1, 2007; 22(3): 827 - 832.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. J. Churchill, J. G. Carter, H. C. Lovell, C. Ramsden, S. J. Turner, A. Yeung, J. Escardo, and D. Atan
VEGF polymorphisms are associated with neovascular age-related macular degeneration
Hum. Mol. Genet., October 1, 2006; 15(19): 2955 - 2961.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S M Hyder
Sex-steroid regulation of vascular endothelial growth factor in breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
H. Garside, C. Waters, A. Berry, L. Rice, H. C Ardley, A. White, P. A Robinson, and D. Ray
UbcH7 interacts with the glucocorticoid receptor and mediates receptor autoregulation.
J. Endocrinol., September 1, 2006; 190(3): 621 - 629.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
T. Higashi, S. Kyo, M. Inoue, H. Tanii, and K. Saijoh
Novel Functional Single Nucleotide Polymorphisms in the Latent Transforming Growth Factor-{beta} Binding Protein-1L Promoter: Effect on Latent Transforming Growth Factor-{beta} Binding Protein-1L Expression Level and Possible Prognostic Significance in Ovarian Cancer
J. Mol. Diagn., July 1, 2006; 8(3): 342 - 350.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
N. Kataoka, Q. Cai, W. Wen, X.-O. Shu, F. Jin, Y.-T. Gao, and W. Zheng
Population-Based Case-Control Study of VEGF Gene Polymorphisms and Breast Cancer Risk among Chinese Women.
Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1148 - 1152.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. J. Prior, J. M. Hagberg, C. M. Paton, L. W. Douglass, M. D. Brown, J. C. McLenithan, and S. M. Roth
DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1848 - H1855.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
D. S. Faffe, L. Flynt, K. Bourgeois, R. A. Panettieri Jr., and S. A. Shore
Interleukin-13 and Interleukin-4 Induce Vascular Endothelial Growth Factor Release from Airway Smooth Muscle Cells: Role of Vascular Endothelial Growth Factor Genotype
Am. J. Respir. Cell Mol. Biol., February 1, 2006; 34(2): 213 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. M. Summers, B. M. Coupes, M. F. Brennan, S. A. Ralph, C. D. Short, and P. E. C. Brenchley
VEGF -460 genotype plays an important role in progression to chronic kidney disease stage 5
Nephrol. Dial. Transplant., November 1, 2005; 20(11): 2427 - 2432.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. H. Kim, Y. M. Choi, S. H. Choung, J. K. Jun, J. G. Kim, and S. Y. Moon
Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis
Hum. Reprod., October 1, 2005; 20(10): 2904 - 2908.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. S. Seo, S.-S. Lee, S. I. Kim, W. H. Ryu, K. H. Sa, S. U. Kim, S. W. Han, E. J. Nam, J. Y. Park, W. K. Lee, et al.
Influence of VEGF gene polymorphisms on the severity of ankylosing spondylitis
Rheumatology, October 1, 2005; 44(10): 1299 - 1302.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. Bhanoori, K. Arvind Babu, N.G. Pavankumar Reddy, K. Lakshmi Rao, K. Zondervan, M. Deenadayal, S. Kennedy, and S. Shivaji
The vascular endothelial growth factor (VEGF) +405G>C 5'-untranslated region polymorphism and increased risk of endometriosis in South Indian women: a case control study
Hum. Reprod., July 1, 2005; 20(7): 1844 - 1849.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Lu, X.-O. Shu, Y. Cui, N. Kataoka, W. Wen, Q. Cai, Z.-X. Ruan, Y.-T. Gao, and W. Zheng
Association of Genetic Polymorphisms in the VEGF Gene with Breast Cancer Survival
Cancer Res., June 15, 2005; 65(12): 5015 - 5019.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
W M Howell, S Ali, M J Rose-Zerilli, and S Ye
VEGF polymorphisms and severity of atherosclerosis
J. Med. Genet., June 1, 2005; 42(6): 485 - 490.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Jin, K. Hemminki, K. Enquist, P. Lenner, E. Grzybowska, R. Klaes, R. Henriksson, B. Chen, J. Pamula, W. Pekala, et al.
Vascular Endothelial Growth Factor Polymorphisms in Relation to Breast Cancer Development and Prognosis
Clin. Cancer Res., May 15, 2005; 11(10): 3647 - 3653.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. J. Lee, S. Y. Lee, H.-S. Jeon, S. H. Park, J. S. Jang, G. Y. Lee, J. W. Son, C. H. Kim, W. K. Lee, S. Kam, et al.
Vascular Endothelial Growth Factor Gene Polymorphisms and Risk of Primary Lung Cancer
Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 571 - 575.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Liu, F. Innocenti, M. H. Wu, A. A. Desai, M. E. Dolan, E. H. Cook Jr., and M. J. Ratain
A Functional Common Polymorphism in a Sp1 Recognition Site of the Epidermal Growth Factor Receptor Gene Promoter
Cancer Res., January 1, 2005; 65(1): 46 - 53.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
C E Waters, A Stevens, A White, and D W Ray
Analysis of co-factor function in a glucocorticoid-resistant small cell carcinoma cell line
J. Endocrinol., November 1, 2004; 183(2): 375 - 383.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. W. I. Cooke, J. A. Drury, R. Mountford, and D. Clark
Genetic Polymorphisms and Retinopathy of Prematurity
Invest. Ophthalmol. Vis. Sci., June 1, 2004; 45(6): 1712 - 1715.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Wu, J. Richer, K. B. Horwitz, and S. M. Hyder
Progestin-Dependent Induction of Vascular Endothelial Growth Factor in Human Breast Cancer Cells: Preferential Regulation by Progesterone Receptor B
Cancer Res., March 15, 2004; 64(6): 2238 - 2244.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. Ray, M. Mishra, S. Ralph, I. Read, R. Davies, and P. Brenchley
Association of the VEGF Gene With Proliferative Diabetic Retinopathy But Not Proteinuria in Diabetes
Diabetes, March 1, 2004; 53(3): 861 - 864.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stevens, A.
Right arrow Articles by Ray, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stevens, A.
Right arrow Articles by Ray, D. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online